DSP-1181: an AI-created drug candidate enters Phase I
Sumitomo Dainippon Pharma and Exscientia announced the start in Japan of a Phase I study of DSP-1181, a 5-HT1A serotonin receptor agonist created with the Centaur Chemist platform, with obsessive-compulsive disorder as the first indication. The companies said exploratory research took under 12 months versus a typical 4.5 years. The announcement gives no efficacy results. In the January 31, 2022 investor-call transcript, Sumitomo said development was discontinued because the candidate did not meet the expected Phase I criterion.
Technology: Centaur Chemist (molecule-design platform)
Publication: Announcement only · Test context: Test context unspecified in annotation. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Announcement only
- Test type: not reported
- Tested: Not reported
- Still unknown: Not reported
- AI role: Candidate created in joint research with Exscientia using its Centaur Chemist AI platform; the page does not describe what the AI did beyond design.
Evidence sources: https://www.sumitomo-pharma.com/news/20200130.html
The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 1/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.